Last 33 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.30 | — | — | — | — | — | — | — | 10.80 | — | 7.79 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.57 | 56.63 | 3.79 | 0.97 | 0.61 | 0.50 | 0.50 | 0.76 | 1.06 | 1.31 | 1.03 | 1.43 | 3.74 |
| — | +11317.0% | +660.5% | +27.1% | -42.6% | -62.1% | -51.6% | -46.8% | -71.6% | -86.7% | -92.9% | -92.0% | -81.2% | |
| P/B Ratio | 0.45 | 0.64 | 0.85 | 1.44 | 0.73 | 0.55 | 0.60 | 0.85 | 0.88 | 1.33 | 0.97 | 1.51 | 6.43 |
| — | +17.2% | +40.8% | +69.3% | -16.6% | -59.1% | -37.7% | -43.5% | -86.3% | -90.7% | -96.1% | -94.7% | -77.8% | |
| P/FCF | — | — | 1.91 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | 2.76 | — | 6.01 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 3.10 | — | 6.71 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BioNexus Gene Lab Corp.'s operating margin was -2501.7% in Q1 2026, down 2288.3 pp QoQ and down 2472.7 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -692.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 719.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.6% | -99.5% | -0.8% | 14.8% | 16.3% | 16.1% | 12.3% | 12.4% | 14.6% | 15.3% | 11.7% | 13.9% | 13.2% |
| — | -719.1% | -106.7% | +19.6% | +11.4% | +4.9% | +4.5% | -10.5% | +10.5% | -1.2% | -1.8% | +19.3% | +35.2% | |
| Operating Margin | -42.5% | -2501.7% | -213.3% | -27.6% | -27.0% | -28.9% | -16.5% | -50.9% | 13.1% | -3.3% | 11.3% | -99.0% | -10.6% |
| — | -8545.1% | -1193.6% | +45.7% | -306.1% | -772.2% | -246.0% | +48.6% | +223.8% | -55.8% | +361.4% | -3809.7% | -91.0% | |
| Net Margin | -40.2% | -2379.7% | -214.2% | -27.9% | -27.3% | -29.2% | -13.8% | -51.1% | 10.1% | -4.4% | 13.5% | -102.2% | -10.1% |
| — | -8058.9% | -1451.9% | +45.5% | -370.4% | -569.6% | -202.0% | +49.9% | +199.8% | -49.9% | +344.7% | -3299.2% | -81.0% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -35.2% | -6.5% | -13.4% | -9.9% | -8.1% | -7.7% | -3.9% | -14.2% | 2.1% | -1.1% | 3.2% | -33.3% | -4.1% |
| — | +16.0% | -241.4% | +30.4% | -482.3% | -609.3% | -223.8% | +57.4% | +150.9% | -4.5% | +232.5% | -2752.8% | -108.3% | |
| ROA | -30.3% | -3.6% | -12.3% | -8.3% | -6.5% | -6.3% | -3.3% | -12.2% | 1.8% | -0.9% | 2.7% | -26.9% | -3.2% |
| — | +43.0% | -277.8% | +31.6% | -465.1% | -580.6% | -220.9% | +54.9% | +155.4% | -12.7% | +241.7% | -2714.4% | -103.9% | |
| ROIC | -44.8% | -8.0% | -14.7% | -9.6% | -8.1% | -10.9% | -6.5% | -20.4% | 4.9% | -1.1% | 3.5% | -47.8% | -4.6% |
| — | +26.7% | -127.2% | +53.0% | -267.3% | -891.8% | -282.8% | +57.4% | +205.8% | -33.4% | +284.8% | -5033.7% | -141.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 55.6% YoY to 6.52x, strengthening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 |
| — | +3.9% | -19.2% | +11.7% | +6.1% | +98.3% | +66.7% | +68.5% | +222.1% | +62.5% | +78.2% | +255.3% | +65.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 0.81 | — | 0.51 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.46 | 6.52 | 10.46 | 8.30 | 3.63 | 4.19 | 3.81 | 4.98 | 5.60 | 4.61 | 4.93 | 5.03 | 2.79 |
| — | +55.6% | +174.7% | +66.8% | -35.2% | -9.0% | -22.8% | -1.1% | +101.2% | +31.9% | +64.2% | +24.1% | -27.4% | |
| Quick Ratio | 9.16 | 5.69 | 9.16 | 6.81 | 2.94 | 3.44 | 3.10 | 3.99 | 4.87 | 3.98 | 4.24 | 4.36 | 2.16 |
| — | +65.4% | +195.8% | +70.6% | -39.6% | -13.6% | -26.9% | -8.3% | +124.9% | +36.4% | +68.3% | +34.8% | -23.6% | |
| Interest Coverage | -151.73 | -175.20 | -315.66 | — | -125.29 | -119.56 | -71.61 | -215.99 | 57.85 | -16.96 | 61.37 | -593.69 | -89.48 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BGLC stock.
BioNexus Gene Lab Corp.'s current P/E is -1.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioNexus Gene Lab Corp.'s current operating margin is -42.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioNexus Gene Lab Corp.'s business trajectory between earnings reports.